Ravi Visswanathan

423 citations
3 papers · 38 indexed · h-index 3
Topics
Pancreatic and Hepatic Oncology Research (2 papers)Nanoparticle-Based Drug Delivery (1 paper)Cancer Genomics and Diagnostics (1 paper)
Partner nations
United StatesJapan

In The Last Decade

Ravi Visswanathan

3 papers receiving 36 citations

Peers

Ravi Visswanathan
Comparison fields: 5 of 35
  • Molecular Biology 14
  • Pulmonary and Respiratory Medicine 9
  • Oncology 8
  • Biomedical Engineering 6
  • Pharmaceutical Science 4
Replace Alberto Martín‐Lorenzo with:
Alberto Martín‐Lorenzo Spain
Q. T. Tao China
Danny Shih United States
Cristian Ruiz-Moreno Netherlands
Valerie Irizarry-Negron United States
Andy He United States
Yujia He China
Madona Sakkal France
Ariana Hardy United States
Noella Bih United States
Ravi Visswanathan relative to Alberto Martín‐Lorenzo Spain Alberto Martín‐Lorenzo's profile →
Citations per field
00.5×
Alberto Martín‐Lorenzo · 1×
Citations per year

Countries citing papers authored by Ravi Visswanathan

Since Specialization
Citations

This map shows the geographic impact of Ravi Visswanathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravi Visswanathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravi Visswanathan more than expected).

Fields of papers citing papers by Ravi Visswanathan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ravi Visswanathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravi Visswanathan. The network helps show where Ravi Visswanathan may publish in the future.

Co-authorship network of co-authors of Ravi Visswanathan

This figure shows the co-authorship network connecting the top 25 collaborators of Ravi Visswanathan. A scholar is included among the top collaborators of Ravi Visswanathan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravi Visswanathan. Ravi Visswanathan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

About Ravi Visswanathan

Ravi Visswanathan is a scholar working on Genetics, Hematology and Biomaterials, having authored 3 papers that have together received 38 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (2 papers), Nanoparticle-Based Drug Delivery (1 paper) and Cancer Genomics and Diagnostics (1 paper). The work is most often cited by research in Pharmaceutical Science (4 citations), Modeling and Simulation (2 citations) and Process Chemistry and Technology (1 citation). Ravi Visswanathan has collaborated with scholars based in United States and Japan. Frequent co-authors include Judy Lucas, Gang Li, Paolo Vicini, Erica L. Bradshaw‐Pierce, Mary E. Spilker, Xiaoying Chen, Shinji Yamazaki, Zhenhua Gu, Christopher L. Holliman and Chandrasekar Durairaj. Their work appears in journals such as Analytical Chemistry, Clinical Cancer Research and Clinical Pharmacology in Drug Development.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026